EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Association Between NT-Probnp Changes and Clinical Outcomes in Paediatric Patients with Heart Failure: Insights from PANORAMA-HF and PARADIGM-HF

Robert Shaddy iD, Jianjian Gong, Tania Garito, Susan Solar-Yohay, Sijia Zhang, Margaret F Prescott, Damien Bonnet, Paul F Kantor, Michael Burch, Chad Mao, Antoinette Cilliers, Charles Canter und 6 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15326 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Robert Shaddy und 17 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Los Angeles and the Keck School of Medicine of the University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Peptide Fragments, Natriuretic Peptide, Brain, Heart Failure, Aminobutyrates. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52 weeks. This post hoc analysis aims to correlate changes in NT-proBNP levels with clinical outcomes in PANORAMA-HF patients receiving either sacubitril/valsartan or enalapril. Additionally, NT-proBNP reductions in the paediatric population were compared with a subset of adult heart failure with reduced ejection fraction (HFrEF) patients from the PARADIGM-HF trial. Methods and results This post hoc analysis utilized data from Part 2 of the PANORAMA-HF trial. Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed. The paediatric HF population from PANORAMA-HF was categorized into age groups (AG): AG1 (aged 6 to <18 years), AG2a (aged 2 to <6 years) and AG3a (aged 1 month to <2 years). The Cox proportional hazard model evaluated the relationship between NT-proBNP and clinical outcomes. Analysis of 361 paediatric patients (sacubitril/valsartan, n = 179; enalapril, n = 182) demonstrated overall higher baseline NT-proBNP levels in younger AGs. At Week 52, both treatment groups exhibited reduced NT-proBNP levels across all AGs. Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children. Strong associations between NT-proBNP levels and HF clinical outcomes were observed in paediatric populations in PANORAMA-HF and in adult DCM patients with HFrEF in PARADIGM-HF. Doubling of NT-proBNP levels was associated with a ≥1.7-fold increased risk of HF clinical events, while halving of the levels correlated with a 52% reduction in the risk of clinical events.

Conclusions

This is the first prospective, randomized large-scale study to demonstrate a strong correlation between NT-proBNP levels and risks of HF clinical events in paediatric patients with HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide FragmentsNatriuretic Peptide, BrainHeart FailureAminobutyratesStroke VolumeVentricular Function, LeftHumansFemaleMaleChildBiphenyl CompoundsAdolescentValsartanDrug CombinationsAngiotensin Receptor AntagonistsTetrazolesBiomarkersTreatment OutcomeEnalaprilFollow-Up StudiesChild, PreschoolAdult

Stichwörter der Autor:innen

Left ventricular systolic dysfunctionNT‐proBNPPaediatric heart failureSacubitril/valsartan

Substanzen

Peptide FragmentsNatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Biphenyl CompoundsAminobutyratesValsartanDrug CombinationsAngiotensin Receptor Antagonistssacubitril and valsartan sodium hydrate drug combinationTetrazoles

Autor:innen und Institutionen

  • Children's Hospital Los Angeles and the Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
  • Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Pharma, Shanghai, China.
  • M3C-Necker, Congenital and Paediatric Cardiology Department, Hospital Necker-Enfants Malades, University of Paris Cité, Paris, France.
  • Great Ormond Street Hospital for Children, London, UK.

ORCID-Profile: Robert Shaddy

Förderung

  • Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Shaddy, R., Gong, J., Garito, T., Solar-Yohay, S., Zhang, S., Prescott, M. F., Bonnet, D., Kantor, P. F., Burch, M., Mao, C., Cilliers, A., Canter, C., Law, Y., Grutter, G., Wang, J. K., Jeewa, A., Rossano, J., & PANORAMA‐HF investigators (2025). Association Between NT-Probnp Changes and Clinical Outcomes in Paediatric Patients with Heart Failure: Insights from PANORAMA-HF and PARADIGM-HF. ESC Heart Failure. https://doi.org/10.1002/ehf2.15326

Vancouver

Shaddy R, Gong J, Garito T, Solar-Yohay S, Zhang S, Prescott MF, et al. Association Between NT-Probnp Changes and Clinical Outcomes in Paediatric Patients with Heart Failure: Insights from PANORAMA-HF and PARADIGM-HF. ESC Heart Failure. 2025. doi:10.1002/ehf2.15326

BibTeX
@article{Shaddy2025,
  author = {Shaddy, Robert and Gong, Jianjian and Garito, Tania and Solar-Yohay, Susan and Zhang, Sijia and Prescott, Margaret F and Bonnet, Damien and Kantor, Paul F and Burch, Michael and Mao, Chad and Cilliers, Antoinette and Canter, Charles and Law, Yuk and Grutter, Giorgia and Wang, Jou Kou and Jeewa, Aamir and Rossano, Joseph and PANORAMA‐HF investigators, PANORAMA‐HF investigators},
  title = {Association Between NT-Probnp Changes and Clinical Outcomes in Paediatric Patients with Heart Failure: Insights from PANORAMA-HF and PARADIGM-HF},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15326}
}
Kostenlos starten →